Vinay Prasad's abrupt resignation from the FDA's Center for Biologics Evaluation and Research (CBER) has elicited mixed reactions within the biotech sector. Prasad's tenure was marked by controversial decisions, including a halt on Sarepta's Duchenne muscular dystrophy gene therapy, leading to industry and political backlash from conservative groups and influential figures. The FDA Commissioner Marty Makary and HHS Secretary Robert F. Kennedy Jr. initially opposed Prasad's removal, which was ultimately overridden by President Trump amid mounting pressure. This leadership disruption has created uncertainty about the FDA's regulatory trajectory and the future of biologics oversight.